A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

Completed · Phase 3

Conditions studied: Overactive Bladder

In brief

To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.

Key facts

Study ID

NCT00425100

Run by

Pfizer

People needed

516

Starts

2007-01-01

Expected to finish

2007-10-01

Last updated by the study team

2018-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per 24 h documented in the baseline bladder diary)
• OAB patients dissatisfied with their prior therapy with tolterodine

You may not qualify if…

• Patients with any contraindication to fesoterodine usage, e.g., urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug or its ingredients.
• Patients with significant hepatic and renal disease or other significant unstable diseases.
• OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Where it is running

• Pfizer Investigational Site — Huntsville, Alabama, United States
• Pfizer Investigational Site — La Mesa, California, United States
• Pfizer Investigational Site — Orangevale, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Aurora, Illinois, United States
• Pfizer Investigational Site — Pratt, Kansas, United States
• Pfizer Investigational Site — Shreveport, Louisiana, United States
• Pfizer Investigational Site — Milford, Massachusetts, United States
• Pfizer Investigational Site — Omaha, Nebraska, United States
• Pfizer Investigational Site — Woodlane, New Jersey, United States
• Pfizer Investigational Site — Kingston, New York, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Poughkeepsie, New York, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Bethany, Oklahoma, United States
• Pfizer Investigational Site — Eugene, Oregon, United States
• Pfizer Investigational Site — Sellersville, Pennsylvania, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States
• Pfizer Investigational Site — Milwaukee, Wisconsin, United States
• Pfizer Investigational Site — Brussels, Belgium
• Pfizer Investigational Site — Homewood, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.